Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

Parkinson's Disease Clinical Trial

— PERFORM  

Official title:

Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an "On" Versus "End-of-Dose-Off" Motor State

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02549573
• Other study ID #: USWM-AP1-4002
• Status: Terminated
• Phase: Phase 4
• Start date: January 2016
• Est. completion date: December 2016

Study information

• Verified date: December 2017
• Source: Supernus Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine if PT intervention will be improved while in the "on" motor state vs. the "end-of-dose-off" motor state during the PT Intervention Visit in subjects with PD.

Description:

Multicenter, outpatient trial to evaluate PT outcomes in subjects diagnosed with PD and currently using APOKYN. Those subjects who satisfy all eligibility criteria will be randomized to 2 treatment groups:

1. "APO+" (APOKYN treatment before the PT Intervention Visit) and;

2. "APO-" (APOKYN treatment withheld before the PT Intervention Visit).

The study will have:

• Baseline Assessment Visit(s) - 1 day at Investigator's clinic and PT clinic

• APOKYN Response Verification Visit - 1 day

• PT Intervention Visits - for 6 weeks

• End-of-study Assessment Visit(s) - 1 day at Investigator's clinic and PT clinic All subjects will participate in a standardized PT intervention. In both treatment groups, ALL subjects will arrive for the PT Intervention Visit in an "end-of-dose-off" motor state. The "end-of-dose-off" motor state will be achieved by the subject withholding his/her carbidopa/levodopa dose and APOKYN dose for at least 3 hours before the PT Intervention Visit. It is hypothesized that the outcome of PT will be improved when subjects are in the "on" motor state during PT Intervention visits compared with being in the "end-of-dose-off" motor state during PT Intervention visits.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 78 Years

Eligibility

Inclusion Criteria:

• Able to understand and sign an Investigational Review Board (IRB)-approved written informed consent and privacy language (e.g., Health Insurance Portability and Accountability Act (HIPAA) authorization) as per national regulations before any study-related procedures are performed.

• Must have a diagnosis of idiopathic PD.

• Adult male or female 18 to 78 years of age, inclusive.

• Currently using APOKYN, per the Package Insert, for at least 4 weeks before Baseline Assessment Visit(s).

• Currently using carbidopa/levodopa therapy at a steady maintenance dose, representing a stable treatment regimen in the opinion of the Investigator, for at least 4 weeks before Baseline Assessment Visit(s).

• Able to walk 50 feet independently (cane permissible) at the Baseline Assessment Visit.

• Meet all of the following parameters to demonstrate an optimal response to APOKYN at the APOKYN Response Verification Visit: must be "on" in the opinion of the subject and investigator within 20 minutes after the APOKYN injection; and have a motor state improvement of >25% per the Movement Disorder Society (MDS)-UPDRS Motor Score (Part III), within 20 minutes after the APOKYN injection, as compared to pre-injection.

• Willing and able to comply with scheduled visits, treatment plan, other study-related procedures, and have available caregiver to provide transportation to clinic visits as needed.

Exclusion Criteria:

• Received PT targeting Parkinson's disease within 6 months before Baseline Assessment Visit(s).

• Received any investigational (i.e., unapproved) drug product within the last 30 days (or 5 half-lives, whichever is longer) before the Baseline Assessment Visit(s).

• Currently taking, or likely to need to take at any time during the course of the study, any 5HT3 antagonist (i.e., ondansetron, granisetron, dolasetron, palonosetron, alosetron).

• Currently on or likely to transition to the DUOPA (carbidopa and levodopa enteral suspension) during the course of the study.

• Has orthostatic hypotension (defined as >30 mmHg decrease in systolic blood pressure or >15 mmHg decrease in diastolic blood pressure within 2 minutes of standing from a supine position) at the Baseline Assessment Visit(s), or within 20 minutes following APOKYN injection at the APOKYN Verification Visit.

• Has a score of 24 or higher on the Modified Physical Performance Test (M-PPT).

• Has a score of 80% or higher on the Activities-specific Balance Confidence Scale (ABC).

• Has any significant current medical disorder, physical, or mental condition that would, in the Investigator's opinion, represent a hazard to the subject or prevent the subject from completing the study.

• Subjects with dementia, in the Investigator's opinion, or subjects with a Montreal Cognitive Assessment (MoCA) <18.

Related Conditions & MeSH terms

• Motor Symptoms
• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• APOKYN
Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.

Behavioral:
• Physical Therapy
All subjects will participate in a standardized PT intervention

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39)	PDQ-39 is a scale measuring subject reported aspects of functioning and well-being. Each of the 39 items is rated using a 5-points Likert scale, with 0 for never having difficulties/problems and 4 for all always having difficulties/problems. The total score is the sum of the 39 items, with a minimum score of 0 and a maximum score of 156. A negative change from baseline represents an improvement in functioning and well-being.	Baseline and after week 6
Other	Change From Baseline in Parkinson's Fatigue Scale (PFS-16)	PFS-16 is a subject-reported scale evaluating the physical effects of fatigue and its impact on daily function, with a minimum score of 16 and a maximum score of 80. Ratings are based on feelings and experiences over the prior 2 weeks, with scoring ranging from 1 (strongly disagree) to 5 (strongly agree), where lower scores are associated with less fatigue and higher scores are associated with greater fatigue.; A negative change from baseline represents an improvement in the physical effects of fatigue and the impact on daily function. .	Baseline and after week 6
Other	Hospital Anxiety and Depression Scale - Change From Baseline in Anxiety	The Hospital Anxiety and Depression Scale is a 14-item Investigator-rated scale designed to determine levels of anxiety and depression in people with physical health problems. Seven items relate to anxiety and 7 items related to depression, where the scale ranges from 0 (best score possible) to 21 (worst score possible). A negative change from baseline represents a decrease in anxiety.	Baseline and after week 6
Other	Number of Participants in Each Category of Patient Global Impression of Change (PGI-C)	Self reported (caregiver, if applicable) impression of change in the subject's symptoms from baseline assessment visit to end of study assessment, on a 7-point scale ranging from much improved to very much worse.	After week 6
Other	Change From Baseline in Number of Falls as Reported by the Subject in the Past 1 Week	Subject reported number of falls. A negative change from baseline represents a decrease in the frequency of falls.	Baseline and after week 6
Other	Change From Baseline in Patient Global Impression of Severity (PGI-S)	Self reported (caregiver, if applicable) impression of the severity of the subject's illness on a 7-point scale ranging from normal (1) to among the most extremely ill subjects (7). A negative change from baseline represents a decrease in the severity of the subject's illness.	Baseline and after week 6
Other	Hospital Anxiety and Depression Scale - Change From Baseline in Depression	The Hospital Anxiety and Depression Scale is a 14-item Investigator-rated scale designed to determine levels of anxiety and depression in people with physical health problems. Seven items relate to anxiety and 7 items related to depression, where the scale ranges from 0 (best score possible) to 21 (worst score possible). A negative change from baseline represents a decrease in depression.	Baseline and after week 6
Primary	Change From Baseline in Activities-specific Balance Confidence (ABC) Scale	Scale from 0 to 100% where an increase in percent represents an improvement in balance confidence.	Baseline and after week 6
Secondary	Change From Baseline in Movement Disorder Societies Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination)	MDS-UPDRS Part III is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 72 (worst score possible). A negative change from baseline represents an improvement in motor function.	Baseline and after week 6
Secondary	Change From Baseline in Modified Physical Performance Test (M-PPT)	Investigator scale assessing 9 domains of physical functioning where total scores range from 0 to 28 with higher scores indicating better physical performance. A positive change from baseline represents an improvement in physical performance.	Baseline and after week 6
Secondary	Change From Baseline in Timed-Up-and-Go (TUG) Test	Test captures the amount of time for a subject to get up from an arm chair, walk 3 meters, turn around, walk back to chair, and sit. A negative change from baseline represents an improvement of physical function.	Baseline and after week 6
Secondary	Change From Baseline in 6-Minute Walk Test (6MWT)	Objective performance based measure of functional exercise capacity that measures the distance a subject can cover on a 30 meter flat walking area over 6 minutes. A positive change from baseline represents an improvement in the distance walked (ft) in 6 minutes.	Baseline and after week 6
Secondary	Change From Baseline in Montreal Cognitive Assessment (MoCA)	The MoCA is a validated, 30-point test (sum of the 6 domains), with scores ranging from 0 (worst) to 30 (best). The test is designed to assess several cognitive domains, including visuospatial abilities (5 points), animal naming (3 points), attention (6 points), language (3 points), abstraction (2 points), delayed recall (5 points), and orientation to time and place (6 points). Total MoCA scores higher than 26 indicate normal cognitive function. A positive change from baseline represents an improvement in cognitive function.	Baseline and after week 6
Secondary	Change From Baseline in MDS-UPDRS Part I A	MDS-UPDRS Part I A is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 24 (worst score possible). A negative change from baseline represents an improvement in non-motor experiences of daily living (investigator rated).	Baseline and after week 6
Secondary	Number of Participants in Each Category of Clinical Global Impression of Change (CGI-C)	Investigator's impression of change in the subject's symptoms from baseline assessment visit to end of study assessment, on a 7-point scale ranging from very much improved to very much worse.	After week 6
Secondary	Change From Baseline in MDS-UPDRS Part II	MDS-UPDRS Part II is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 52 (worst score possible). A negative change from baseline represents an improvement in motor experience of daily living.	Baseline and after week 6
Secondary	Change From Baseline in MDS-UPDRS Part IV	MDS-UPDRS Part IV is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 24 (worst score possible). A negative change from baseline represents fewer motor complications.	Baseline and after week 6
Secondary	Change From Baseline in MDS-UPDRS Part I B	MDS-UPDRS Part I B is a sub-scale of MDS-UPDRS. Sub-scale scores range from 0 (best score possible) to 28 (worst score possible). A negative change from baseline represents an improvement in non-motor experiences of daily living (subject rated).	Baseline and after week 6
Secondary	Change From Baseline in Clinical Global Impression of Severity (CGI-S)	Investigator's impression of the severity of the subject's illness on a 7-point scale ranging from normal (1) to among the most extremely ill subjects (7). A negative change from baseline represents a decrease in the severity of the subject's illness.	Baseline and after week 6